Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Neurology
Published in: Current Treatment Options in Neurology 3/2018

Open Access 01-03-2018 | Neurologic Manifestations of Systemic Disease (N Scolding, C Rice and A Wilkins, Section Editors)

Treatment of Tuberculous Meningitis and Its Complications in Adults

Authors: Angharad Davis, BSc, MBBS, MRCP, Graeme Meintjes, MBChB, FRCP, FCP, DipHIVMan, MPH, PhD, Robert J. Wilkinson, MA, BM, BCh, DTM&H, PhD, FRCP, FMedSci

Published in: Current Treatment Options in Neurology | Issue 3/2018

Login to get access

Abstract

Purpose of review

Tuberculous meningitis (TBM) is a global health problem. In this review, we systematically evaluate the evidence for current and emerging antimicrobials, host-directed therapies and supportive managements.

Recent findings

Current antimicrobial regimes do not factor the differing ability of drugs to cross the blood-brain barrier. Rifampicin may be more effective at higher doses yet the most recent clinical trial failed to demonstrate survival benefit at 15 mg/kg/day. Dose finding studies suggest that higher doses still may be safe and more effective. Fluoroquinolones are currently listed as important second-line agents in drug-resistant TBM; however, a survival benefit as a first-line agent has yet to be shown. Linezolid may be a promising antimicrobial with good central nervous system penetrance. Dexamethasone reduces mortality in HIV-uninfected individuals yet evidence for its use in HIV co-infection is lacking. Aspirin has anti-inflammatory and anti-thrombotic properties. Small studies have demonstrated efficacy in reducing stroke but further research is required to better understand its effect on controlling the host inflammatory response. Discovery of genetic polymorphisms may direct individualized immune therapies and mediators of the innate immune response may provide targets for the development of novel therapies. There is at present no significant evidence base to guide management of hydrocephalus in HIV co-infection.

Summary

Further clinical trial data is required to improve treatment outcomes in TBM in particularly in regard to the value of high-dose rifampicin, newer antimicrobials with improved central nervous system penetration and host-directed therapies. Supportive measures in particular the management of hydrocephalus in HIV co-infection should be an area for future research.
Literature
1.
World Health Organization. Global tuberculosis report 20th edition. World Health Organization, Geneva; 2015.
2.
Streptomycin in tuberculosis trials committee, Medical Research Council. Streptomycin treatment of tuberculous meningitis. Lancet 1948:251:582–589.
3.
Treatment of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Br Med J 1952:2:735–46.
4.
Nitti V. Results and tolerance of prolonged rifampicin treatment in recent and chronic forms of pulmonary tuberculosis. Respiration. 1971;28(Suppl):57–69.CrossRef
5.
6.
7.
WHO. Treatment of tuberculosis guidelines. World Health Organisation. Geneva, 2010.
8.
9.
10.
Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Resp Dis. 1993;148(3):650e5.
11.
Mitchison DA. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2000;4(9):796e806.
12.••
Heemskerk AD, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med. 2016;374:124–34. https://​doi.​org/​10.​1056/​nejmoa1507062. A randomized, double-blind, placebo-controlled trial demonstrating no survival benefit in patients treated with higher dose rifampicin (15 mg/kg/day) and levofloxacin in addition to standard treatment for the first 8 weeks of treatment.CrossRefPubMed
13.
14.
15.
Long MW, Snider DE Jr, Farer LS. U.S. public health service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev. Respir Dis. 1979;119(6):879–94.
16.
17.•
18.
East African/British Medical Research Councils. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 1972;1:1079e85.
19.
Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1980;121:939e49.
20.
Botha FJH, Sirgel FA, Parkin DP, Van de Wal BW, Donald PR, Mitchison DA. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J. 1996;86:155e8.
21.
22.
WHO. The shorter MDR-TB shorter regimen. World Health Organization, Geneva; 2016
23.
Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Resp Dis. 1985;131:352–6.PubMed
24.
25.
26.
27.
Te Brake L, et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. Int J of Antimicr Agents. 2015;45(5):496–503.CrossRef
28.
Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Targets Infect Dis. 2001:181–99.
29.
Brickner SJ, Barbachyn MR, Hutchinson DK, et al. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious Gram- positive infections. J Med Chem. 2008;51:1981–90.CrossRefPubMed
30.
Fortun J, Martin-Davila P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother. 2005;56:180–5.CrossRefPubMed
31.
von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten cases. J Infect. 2006;52:92–6.CrossRefPubMed
32.
Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest. 2008;134:187–92.CrossRefPubMed
33.
Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40:1430–42.CrossRefPubMed
34.
Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2010;50:49–55.CrossRefPubMed
35.
Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J. 2009;34:387–93.CrossRefPubMed
36.
Anger H, Dworkin F, Sharma S, et al. Linezolid use for the treatment of multi-drug resistant and extensively drug resistant tuberculosis, New York City, 2000-6. J Antimicrob Chemother. 2010;65:775–83.CrossRefPubMed
37.
38.
39.
40.
Zhang X, Falagas M, Konstantinos V, Wang R, Win R, Wang J, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7(4):603–15.PubMedPubMedCentral
41.
Lee JY, Kim DK, Lee JK, et al. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicentre, randomized, open-label, phase II trial. Trials. 2017;18:68.CrossRefPubMedPubMedCentral
42.
Li H, Lu J, Liu J, Zhao Y, Ni X, Zhao S. Linezolid is associated with improved early outcomes of childhood tuberculous meningitis. Pediatr Infect Dis J. 2016;35(6):607–10.CrossRefPubMed
43.•
Sun F, Ruan Q, Wang J, Chen S, Jin J, Shao L, et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob Angents Chemother. 2014;58(10):6297–301. A retrospective cohort study of patients with severe TBM demonstrating improved recovery of consciousness and biochemical markers of disease severity in patients treated with linezolid in addition to standard TBM regimens.CrossRef
44.
45.
46.
47.
48.
Shane SJ, Clowater RA, Riley C. The treatment of tuberculous meningitis with cortisone and streptomycin. Can Med Assoc J. 1952;67:13–5.PubMedPubMedCentral
49.
Chotmongkol V, Jitpimolmard S, Thavornpitak Y. Corticosteroid in tuberculous meningitis. Journal of the Medical Association of Thailand. 1996;79(2):83–90.PubMed
50.
Girgis NI, Farid Z, Kilpatrick ME, Sultan Y, Mikhail IA. Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatric Infectious Disease Journal. 1991;10(3):179–83.CrossRefPubMed
51.
Kumarvelu S, Prasad K, Khosla A, Behari M, Randomized AGK. controlled trial of dexamethasone in tuberculous meningitis. Tubercle and Lung Disease. 1994;75(3):203–7.CrossRefPubMed
52.
Lardizabal DV, Roxas AA. Dexamethasone as adjunctive therapy in adult patients with probable TB meningitis stage II and stage III: an open randomised controlled trial. Philippines Journal of Neurology. 1998;4:4–10.
53.
54.
Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226–31.CrossRefPubMed
55.
56.••
Thwaites GE, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351:1741–51. https://​doi.​org/​10.​1056/​nejmoa040573. A randomized, double-blind, placebo-controlled trial demonstrating survival benefit in patients treated with adjunctive dexamethasone in HIV-uninfected individuals. Subgroup analysis in those HIV-coinfection revealed no significant benefit on mortality.CrossRefPubMed
57.
58.
59.
60.
Tsenova L, Bergtold A, Freedman VH, Young RA, Kaplan G. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci U S A. 1999;96:5657–62.CrossRefPubMedPubMedCentral
61.
Schoeman JF, Springer P, Ravenscroft A, Donald PR, Bekker LG, van Rensburg AJ, et al. thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role. J Child Neurol. 2000;15(8):497–503.CrossRefPubMed
62.
Schoeman JF, Springer P, van Rensburg AJ, Swanevelder S, Hanekom WA, Haslett PA, et al. thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol. 2004;19(4):250–7.CrossRefPubMed
63.
64.
65.
66.
67.
68.
69.
70.
Molton JS, Huggan PJ, Archuleta S. Infliximab therapy in two cases of severe neurotuberculosis paradoxical reaction. Med J Aust. 2015;202:156–7.CrossRefPubMed
71.
72.•
Marais S, Lai RPJ, Wilkinson KA, Meintjes G, O’Garra A, Wilkinson RJ. Inflammasome activation underlies central nervous system deterioration in HIV-associated tuberculosis. J Infect Dis. 2017;215(5):677–86. https://​doi.​org/​10.​1093/​infdis/​jiw561. An observation study in HIV-associated TBM to investigate the pathogenesis of immune reconstitution inflammatory syndrome suggesting a dominant role of the innate immune system.PubMed
73.
Rich AR, The pathogenesis of tuberculosis. Charles C Thomas, 1946.
74.
75.
Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;7905:480–4.CrossRef
76.
Palur R, Rajshekhar V, Chandy MJ, Joseph T, Abraham J. Shunt surgery for hydrocephalous in tubercular meningitis: a long-term follow-up study. J Neurosurg. 1991;74:64–9.CrossRefPubMed
77.
78.
79.
80.
81.
82.
83.
84.
Moller K, Larsen FS, Bie P, et al. The syndrome of inappropriate secretion of antidiuretic hormone and fluid restriction in meningitis—how strong is the evidence? Scand J Infect Dis. 2001;33:13–26.CrossRefPubMed
85.
Thwaites GE, Macmullen-Price J, Tran TH, et al. Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study. Lancet Neurol. 2007 Mar;6(3):230–6.CrossRefPubMedPubMedCentral
86.
Schoeman JF, Fieggen G, Seller N, et al. Intractable intracranial tuberculous infection responsive to thalidomide: report of four cases. J Child Neurol. 2006;21(4):301–8.CrossRefPubMed
87.
de la Riva P, Urtasun M, Castillo-Trivino T, et al. Clinical response to thalidomide in the treatment of intracranial tuberculomas: case report. Clin Neuropharmacol. 2013;36(2):70–2.CrossRefPubMed
88.
Roberts MT, Mendelson M, Meyer P, et al. The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports. J Infect. 2003;47(3):251–5.CrossRefPubMed
89.
Thomas MD, Chopra JS, Tuberculous WBNS. meningitis (TBM): a clinical study of 232 cases. J Assoc Physicians India. 1977;25:633–9.PubMed
90.
Dalal PM. Observations on the involvement of cerebral vessels in tuberculous meningitis in adults. In: Goldstein M, Murray, Bolis, Liana, Fieschi, Gorini, editors. Advances in neurology, vol. 25. Raven Press: 1979. p. 149–159.
91.
92.
93.
94.
95.
Hovens MM, Snoep JD, Groeneveld Y, Frölich M, Tamsma JT, Huisman MV. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diab Obes Metab. 2008;10:668–74.CrossRef
96.
Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell. 2012;148:434–46.CrossRefPubMedPubMedCentral
97.
98.
Metadata
Title
Treatment of Tuberculous Meningitis and Its Complications in Adults
Authors
Angharad Davis, BSc, MBBS, MRCP
Graeme Meintjes, MBChB, FRCP, FCP, DipHIVMan, MPH, PhD
Robert J. Wilkinson, MA, BM, BCh, DTM&H, PhD, FRCP, FMedSci
Publication date
01-03-2018
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 3/2018
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-018-0490-9